Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice
Sophie V. Fletcher, Mark G. Jones, Elizabeth A. Renzoni, Helen Parfrey, Rachel K. Hoyles, Katherine Spinks, Maria Kokosi, Apollinaris Kwok, Chris Warburton, Vanessa Titmuss, Muhunthan Thillai, Nicola Simler, Toby M. Maher, Christopher J. Brereton, Felix Chua, Athol U. Wells, Luca Richeldi, Lisa G. Spencer
Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Sophie V. Fletcher, Mark G. Jones, Elizabeth A. Renzoni, Helen Parfrey, Rachel K. Hoyles, Katherine Spinks, Maria Kokosi, Apollinaris Kwok, Chris Warburton, Vanessa Titmuss, Muhunthan Thillai, Nicola Simler, Toby M. Maher, Christopher J. Brereton, Felix Chua, Athol U. Wells, Luca Richeldi, Lisa G. Spencer. Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: